The Top 5 Biosimilar Articles for the Week of February 7

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of February 7, 2022.

Number 5: Pooled data from 3 randomized controlled trials on biosimilar pegfilgrastim-cbqv (Udenyca) suggested “similar immunogenicity” to the reference product (Neulasta), investigators concluded.

Number 4: The Biosimilars Forum has appointed Cofounder and President Juliana (Julie) M. Reed, as the new executive director. Reed shared some of her goals for the Biosimilars Forum in an interview with The Center for Biosimilars®.

Number 3: The year 2022 “is set to be a turning point” in the United States, as biosimilars are on their way to delivering $133 billion in aggregate savings by 2025, according to Cardinal Health's “2022 Biosimilars Report: The U.S. Journey and Path Ahead.”

Number 2: Nova Scotia became the fifth province and sixth jurisdiction in Canada to implement a switching policy that allows for reference products to be automatically substituted with biosimilars.

Number 1: Health Canada approved Ontruzant, the fifth Samsung Bioepis biosimilar to be approved for the Canadian market.

To read all of these articles and more, visit centerforbiosimilars.com.